FDA's START program selects Moderna's mRNA-3705 for MMA treatment development.

The FDA selected Moderna's mRNA-3705 for its START pilot program, accelerating the development of an experimental treatment for methylmalonic acidemia (MMA) due to methylmalonic-CoA mutase deficiency. START aims to speed up the development of novel treatments for rare diseases. Moderna's mRNA-3705 is a Phase 1/2 study treatment designed to restore missing or dysfunctional proteins causing MMA.